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We sought to visualize themigration of tumor-associatedmacrophages (TAMs) to tumor lesions and to evaluate the effects of
anti-inflammatory drugs on TAM-modulated tumor progression in mice with colon cancer using a multimodal optical reporter
gene system. Murine macrophage Raw264.7 cells expressing an enhanced firefly luciferase (Raw/effluc) and murine colon
cancer CT26 cells coexpressing Rluc and mCherry (CT26/Rluc-mCherry, CT26/RM) were established. CT26/RM tumor-bearing
mice received Raw/effluc via their tail veins, and combination of bioluminescence imaging (BLI) and fluorescence imaging (FLI)
wasconducted for in vivo imagingofTAMsmigrationand tumorprogression.Dexamethasone (DEX), apotentanti-inflammatory
drug, was administered intraperitoneally to tumor-bearing mice following the intravenous transfer of Raw/effluc cells. The
migrationofTAMsand tumorgrowthwasmonitoredbyserial FLI andBLI.ThemigrationofRaw/effluccells to tumor lesionswas
observedatday1,andBLIsignalswerestill distinctat tumor lesionsonday4.LocalizationofBLIsignals frommigratedRaw/effluc
cells corresponded to that of FLI signals from CT26/RM tumors. In vivo FLI of tumors demonstrated enhanced tumor growth
associated with macrophage migration to tumor lesions. Treatment with DEX inhibited the influx of Raw/effluc cells to tumor
lesions and abolished the enhanced tumor growth associated with macrophage migration. These findings suggest that
molecular imagingapproach forTAMtracking isavaluable tool forevaluating the roleofTAMs in the tumormicroenvironmentas
well as for the development of new drugs to control TAM involvement in the modulation of tumor progression.
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Macrophages are important immune cells involved in the onset,
progression, and manifestation of various pathologic processes, such
as the development of malignant tumors and various inflammatory
diseases [1–4]. They are divided into classically activated macrophages
(M1) and alternatively activated macrophages (M2 or tumor-associated
macrophages, TAMs). M1 macrophages are activated by interferon-γ,
tumor necrosis factor–α, or lipopolysaccharides; they have immunos-
timulatory properties and generate a Th1 immune response. Contrary
to M1 macrophages, M2 macrophages with poor antigen-presenting
capacity suppress Th1 adaptive immunity [5].
Recently, several studies have demonstrated that TAMs not only
facilitate tumor angiogenesis, extracellular matrix degradation, and
remodeling but also promote tumor cell motility [6,7]. Furthermore,direct communication between TAMs and cancer cells results in the
invasion of tumor cells into blood vessels. TAMs are found in the
center of the tumor microenvironment and are important targets for
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biological role of TAMs in cancer and have identified promising
therapeutic drugs to modulate their involvement in tumor progres-
sion. However, analyses of the complex biological, pathological, and
immunological factors involved in the relationship between TAMs
and tumor-bearing hosts are still limited. Therefore, robust and
quantitative techniques are necessary to assess the dynamic functions
of TAMs in tumor microenvironments.
Molecular-genetic imaging strategies are based on a reporter gene
and a complementary reporter probe, which are introduced into cells
to visualize proliferation, localization, and migration in living subjects
[9,10]. Among several reporter gene-based imaging modalities,
optical imaging with bioluminescent or fluorescent reporter genes is
widely used and is useful for cell tracking and for the evaluation of
therapeutic outcomes in various preclinical models owing to their
high sensitivity, simple imaging procedures, and no requirement of
complex imaging facilities, such as positron emission tomography,
single-photon emission computed tomography, and magnetic
resonance imaging (MRI) systems.
In this study, we attempted to demonstrate TAM migration to
tumor lesions using an enhanced firefly luciferase in living mice with
colon cancer. To accomplish this study, we used Raw264 macrophage
cells with characteristics of TAM for optical imaging of the TAM
kinetics. Furthermore, Renilla luciferase (Rluc) and mCherry reporter
genes were introduced to monitor the proliferation of colon cancer
cells in response to TAMs in vitro and in vivo. Finally, the effects of
dexamethasone (DEX, an anti-inflammatory drug) on the migration
of TAMs to tumor lesions as well as on the TAM-mediated
modulation of tumor progression were evaluated using the established
multimodal reporter imaging strategies.Materials and Methods
Animals
Pathogen-free 6-week-old female BALB/c mice were obtained from
SLC Inc. (Shizuoka, Japan). All animal experimental protocols were
approved by the Committee for the Handling and Use of Animals at
Kyungpook National University.
Cells
Murine macrophage Raw264.7 cells were cultured in Dulbecco’s
modified Eagle medium supplemented with 10% fetal bovine serum
and 1% antibiotic-antimycotic (Invitrogen, Carlsbad, CA) at 37°C in
a 5% CO2 atmosphere. Raw264.7 cells were retrovirally transduced
to express both effluc and Thy1.1. The Thy1.1-positive cells were
sorted using CD90.1 MicroBeads (Miltenyi Biotec, Auburn, CA).
The established stable macrophage cells expressing both effluc and
Thy1.1 are herein named as Raw/effluc cells.
The murine colon cancer cell line CT26 was transduced with a
lentivirus coexpressing the Rluc and mCherry genes (GeneCopoeia
Inc., Rockville, MD). Two days later, mCherry-positive cells were
enriched using the FACS Aria III (BD Biosciences, San Jose, CA).
The stable clones coexpressing Rluc and mCherry are named as
CT26/RM cells.
For the luciferase assay, the indicated numbers of parental and
reporter cells were plated in 96-well Black Plates with clear bottoms.
After 24 hours, each well was supplemented with either D-luciferin
(DV Medical Research Innovations, Adrian, MI) or coelenterazine h
(NanoLight, AZ, USA). Bioluminescence imaging (BLI) signals weremeasured using an IVIS Lumina III imaging system (PerkinElmer,
Waltham, MA).
Cellular Proliferation Assay
For the in vitro analysis, CT26/RM cells (1 × 104 cells/well) were
plated without or with Raw/effluc cells (1 × 103 cells/well). After 24
hours, BLI activity was measured with an IVIS Lumina III, and
fluorescence imaging (FLI) was acquired with a fluorescent microscope.
For the in vivo analysis, CT26/RM cells (1 × 106 cells) were mixed
without or with Raw/effluc cells (1 × 105 cells), and these mixtures
were subcutaneously injected to predetermined sites in the mice.
In vivo proliferation rates of CT26/RM cells were determined by BLI
at days 1, 2, and 6 postinjection.
Transwell Migration Assay
To prepare conditioned medium (CM), CT26/RM cells were grown
to 70% to 80% confluence in completed culture media. The medium
was replaced with serum-free RPMI-1640, and cells were cultured for
an additional 48 hours. Raw/effluc cells were resuspended in serum-free
RPMI-1640 and cultured for 48 hours. Medium was collected and
filtered with 0.22-μm filters (Millipore, Billerica, MA). The 8-μm pore
Transwell polycarbonate membrane chambers (Corning, Pittston, PA)
were used. Raw/effluc cells (1 × 105) in 100 μl of serum-free medium
(SFM) were added to the upper chamber. CM from CT26/RM was
added to the lower chamber. The cells were allowed to migrate through
themembrane for 24 hours at 37°C in a 5%CO2 atmosphere. The cells
that migrated to the bottom chamber were collected and counted by
flow cytometry. Events acquired over a fixed time period (60 seconds)
were analyzed using FlowJo analysis software.
In Vivo Study
Study 1. For in vivo tracking of TAMs, CT26/RM was
subcutaneously administered to mice. CT26/RM tumor-bearing mice
were divided into two groups: CT26/RM and CT26/RM+ Raw/effluc.
Either phosphate-buffered saline (PBS) or Raw/effluc cells (5 × 106 in
0.1 ml of PBS) was intravenously transferred to tumor-bearing mice.
BLI (for TAM imaging) was conducted once daily from day 1 to until
day 4 posttransfer of Raw/effluc cells. For tumor imaging, in vivo FLI
with filter settings for mCherry using the IVIS Lumina III was
performed at the indicated times posttransfer of macrophages.
Study 2. To evaluate the effect of DEX (Sigma, St. Louis, MO)
on both TAMs migration as well as on TAMs modulation of tumor
growth, CT26/RM tumor-bearing mice were divided into three
groups: CT26/RM, CT26/RM+Raw/effluc, and CT26/RM+Raw/
effluc+DEX. Mice received 10 mg/kg DEX immediately via
intraperitoneal injection following the transfer of Raw/effluc cells.
Daily treatment with DEX was sustained for 3 days. In vivo BLI and
FLI were performed at the indicated times.
For in vivo BLI, mice received either D-luciferin (for effluc) or
coelenterazine h (for Rluc) via either intraperitoneal or intravenous
injection. BLI was performed at 10 minutes (effluc) or immediately
(Rluc) after the injection of the respective substrate using the IVIS
Lumina III imaging system (PerkinElmer). Grayscale photographic
images and bioluminescent color images were superimposed using
LIVINGIMAGE (version 2.12, PerkinElmer) and IGOR Image
Analysis FX software (WaveMetrics, Lake Oswego, OR). BLI signals
are expressed in units of photons per cm2 per second per steradian
(P/cm2/s/sr). All mice were anesthetized using 1% to 2% isoflurane
gas during imaging.
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For ex vivo imaging of the specimen, mice were sacrificed and
tumors were excised. The excised tumors were placed on an imaging
plate, and images were acquired.
On day 4 posttransfer of Raw/effluc cells, the excised tumors were
incubated with tumor dissociation solution including collagenase D
solution and DNase I to isolate single suspended cells. These cells
were washed with cold PBS twice and labeled with APC-Cy7–
conjugated Thy1.1 antibody (BD Biosciences). The percentage of
Thy1.1-positive cells was determined with flow cytometry (BD
ACCURI C6; BD Biosciences).
Statistical Analysis
All data are expressed as means ± standard deviation from at least
three representative experiments, and statistical significance was
determined using an unpaired Student’s t test. P values less than .05
were considered statistically significant.
Results
Reporter Gene Expression and Its Functional Activity in
Raw/effluc and CT26/RM Cells
Flow cytometric analysis demonstrated higher levels of effluc and
mCherry expression in both Raw/effluc and CT26/RM cells
(Figure 1A). Levels of effluc and mCherry expression in Raw/efflucFigure 1. Tumor-associated macrophages and colon cancer cells expr
Left: Raw/effluc cells indicate cells labeled with either isotype (blue
stable CT26/RM cells (RED). (B) In vitro BLI of either parental Raw264.
of either parental CT26 cells or CT26/RM cells (left) and quantification
with either effluc or Rluc. Tumor-bearing mice received Raw/effluc cand CT26/RM cells were 93% and 87.2%, respectively. Fluorescent
microscopy revealed bright signals of the mCherry protein in CT26/
RM cells (Supplementary Figure 1A). The mCherry gene is
coexpressed with Rluc by the IRES system in CT26/RM cells;
accordingly, similar Rluc expression levels can be inferred, i.e.,
approximately 87.2%. An immunoblotting analysis with an
Rluc-specific antibody indicated Rluc expression in CT26/RM cells
but not in parental CT26 cells (Supplementary Figure 1B).
In vitro BLI of Raw/effluc and CT26/RM cells revealed the cell
number–dependent increase in luciferase signals; there was a strong
correlation between cell number and BLI signals (Figure 1, B and C)
(R2 = 0.89 and 0.95 for Raw/effluc and CT26/RM cells,
respectively). However, no signals were detected in the parental
cells. As illustrated in Figure 1D, distinct FLI signals were detected in
CT26/RM tumors, and the presence of directly injected Raw/effluc
cells at the tumor site was confirmed by BLI.
Enhanced Proliferation of Colon Cancer Cells by TAMs and
Increased Migration Ability by CM of CT26/RM
In vitro BLI with Rluc demonstrated higher proliferation of
CT26/RM+Raw/effluc cells than in those with CT26/RM alone.
Consistent with in vivo BLI, fluorescent microscope imaging revealed
an increased number of cancer cells in CT26/RM+Raw/effluc cells
compared with CT26/RM alone (Figure 2, A and B). Rluc activity wasessing optical reporter genes. (A) FACS analysis of Raw/effluc cells.
) or Thy1.1-specific antibody (red). Right: Parental CT26 (blue) and
7 or Raw/effluc cells and quantification of BLI signal. (C) In vitro BLI
of BLI signal (right). (D) Imaging of TAMs and colon cancer models
ells intratumorally, and then FLI and BLI were conducted.
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CT26/RM-alone and CT26/RM+Raw/effluc cells, respectively (P b .05).
The migration levels of Raw/effluc cells were higher in CM of
CT26/RM cells than in SFM (Figure 2C). The migration levels of
Raw/effluc cells increased in a dose-dependent manner for CM
derived from CT26/RM cells.
Next, we examined whether Raw/effluc cells enhance the
proliferation of CT26/RM cells in vivo. As shown in Figure 2D, no
significant difference of proliferation levels was observed between
CT26/RM+Raw/effluc cells and CT26/RM alone from day 0
postinoculation. However, enhanced proliferation of cancer cells
was distinct at coinjection sites at day 7 postinoculation (P b .05).
In Vivo Imaging of TAM Migration to Tumor Lesions
We serially tracked TAM migration to tumor lesions by combined
BLI and FLI (Supplementary Figure 2A). As illustrated in Figure 3, A
and B, BLI with effluc showed the early distribution of infused Raw/
effluc cells to the lung within 30 minutes posttransfer. Interestingly,
BLI signals from Raw/effluc cells were detected in tumor lesions as
early as day 1 after the transfer of Raw/effluc cells (see red arrow in
Figure 3). Their migration to tumor lesions was still detected at day 4Figure 2. Evaluation of the proliferation level of colon cancer cells an
proliferation of CT26/RM cells by Raw/effluc cells and quantification of
microscopic analysis. CT26/RM cells (1 × 104 cells/well) were plated w
activity was measured with the IVIS Lumina III, and fluorescent micros
addition of Raw/effluc to the upper chamber, the migrated Raw/efflu
collected and counted by flow cytometry. *SFM versus SFM. (D) Imagin
quantification ofBLI signal. CT26/RMcells (1×106 cells)weremixedwi
subcutaneously injected to predetermined sites in mice. *CT26/RM aloposttransfer of Raw/effluc cells despite fluctuation in the BLI signal of
Raw/effluc cells in tumor lesions. The BLI signal emitted from
migrated Raw/effluc cells corresponded well to the FLI signal from
CT26/RM tumors.
Tumors were excised to further validate the localization of migrated
TAMs by ex vivo imaging at day 4 posttransfer of Raw/effluc cells. A
distinct BLI signal from Raw/effluc cells was also observed in excised
tumors by ex vivo BLI (Figure 3A, inset). Furthermore, FACS analysis
with a Thy1.1-specific antibody confirmed the existence of Raw/
effluc cells in excised CT26/RM tumors and showed that levels of
Thy1.1-positive cells ranged from 3.9% to 14.3% (Figure 3, C andD).
However, we cannot see the increase of Thy1.1-positive cells in excised
tumors from mice inoculated with CT26/RM only (Supplementary
Figure 2B).
In Vivo FLI of Enhanced Tumor Growth via
Migrated Raw/effluc Cells
We evaluated the effects of the presence of migrated TAMs on
tumor progression by serially monitoring FLI signals (Supplementary
Figure 3). There was no significant difference between the CT26/
RM-alone group and the CT26/RM+Raw/effluc group at day 0,d the migration ability of TAMs. (A) In vitro BLI showing increased
BLI signal. *CT26/RM versus CT26/RM+Raw/effluc. (B) Fluorescent
ithout or with Raw/effluc cells (1 × 103 cells/well). After 24 hours, BLI
cope images were acquired. (C) Transwell migration assay. After the
c cells to the lower chamber containing CM from CT26/RM were
g of enhanced proliferation of CT26/RM cells by Raw/effluc cells and
thout orwithRaw/effluc cells (1×105 cells), and thesemixtureswere
ne versus CT26/RM+Raw/effluc.
Figure 3. Visualization of TAMsmigration to tumor lesion. (A) In vivo imaging of TAMmigration to tumor lesions (inset: ex vivo imaging of
excised tumor; left: photograph of excised tumor, middle: BLI of Raw/effluc, right: FLI of CT26/RM tumor). (B) Quantification of BLI signal.
Red arrow: Migrated macrophage; blue arrow: tumor site. (C and D) Levels of Thy1.1-positive cells in isolated cells of excised tumor of
mice receiving Raw/effluc cells. The isolated cells of the excised tumor were labeled with Thy1.1-specific antibody (surrogate for effluc),
and the number of Thy1.1-postivie cells was determined with flow cytometry.
Figure 4. In vivo monitoring of tumor growth modulated by migrated TAMs. (A) Visualization of enhanced tumor growth by migrated
TAMs with the mCherry reporter gene and (B) quantification of the mCherry signal in tumors. Tumor-bearing mice received either PBS or
Raw/effluc via the tail vein, and tumor progression was monitored. The localization of infused TAMs in CT26/RM tumors is shown at days
2 and 3 posttransfer by BLI. *CT26/RM alone versus CT26/RM+Raw/effluc.
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Interestingly, in vivo FLI of tumor growth showed higher tumor growth
in the CT26/RM+Raw/effluc group than in the CT26/RM-alone
group. A significant difference in tumor growth was confirmed by serial
imaging between day 7 and day 11 posttransfer of Raw/effluc
cells (Figure 4B, P b .05). The migration of infused Raw/effluc
cells to tumor lesions was also detected at days 2 and 4 posttransfer of
Raw/effluc cells (see red arrow in Figure 4A).
Evaluation of the Effects of DEX on Both Macrophage
Migration to Tumor Lesions and Modulated Tumor
Progression with Combined BLI and FLI
Next, we examined the DEX effects on both TAM migration to
tumors and modulation of tumor growth by combined BLI and FLI
(Supplementary Figure S4). Treatment with DEX resulted in a
significant inhibition of Raw/effluc infiltration to tumor lesions when
compared with the vehicle-treated group based on in vivo BLI
(Figure 5A). In vivo FLI of tumor growth demonstrated that the rate
of tumor growth is significantly higher in the CT26/RM+Raw/effluc
group than the CT26/RM alone group (Figure 5, B and C; P b .05).
Interestingly, enhanced tumor growth via Raw/effluc cells almost
completely disappeared in the DEX-treated group. The relative (%)
increases in FLI signals between day 0 and day 11 (the day after the
transfer of Raw/effluc cells) were 299.0 ± 72%, 539.1 ± 78.8%, and
304.8 ± 70.6% in the CT26/RM-alone, CT26/RM+Raw/effluc, and
DEX-treated groups, respectively (Figure 5D,P b .05, CT26/RM+Raw/effluc
group versus DEX-treated group).Discussion
Noninvasive imaging of TAMs enabling the real-time monitoring of
their distribution in tumor-bearing mice [11] is an attractive research
area. It has been typically accomplished by the use of several imaging
probes, such as optical imaging probes [12,13], iron oxide–based
MRI probes [14], radioisotope-labeled mannose functionalized
liposomes [15], and nanobodies [16]. Both MRI and nuclear imaging,
or even fluorescence imaging using dye-labeled probes, havemuchmore
potential than BLI (the strategy used in this study) for clinical use. So
far, BLI can only be used in preclinical studies; however, MRI and
nuclear imaging are routinely used in the clinical practice.
Reporter gene-based multimodal optical imaging has been
extensively investigated to simultaneously monitor the biological
behavior of several cells of interest, such as immune effectors, stem
cells, and cancer cells, owing to its high sensitivity, easy application,
and the lack of a need for expensive facilities and complex synthesis
procedures [9,10]. Using BLI, it is possible to visualize the
localization, proliferation, and migration of various cells, e.g., to
track tumor progression and the recruitment of immune effectors
simultaneously, as different substrates are used for in vivo imaging of
the effluc (D-luciferin) and Rluc (coelenterazine) genes. Moreover,
FLI with monomeric far red fluorescent reporters, such as the
mCherry and tdTomato proteins, enables the serial monitoring of the
expression of genes of interest and tumor growth, without additional
substrate injections, in living mice [17,18].
In the current study, we have succeeded in serial monitoring of the
migration of TAMs to tumor lesions with effluc and evaluation of the
effects of TAMs on tumor progression with the mCherry reporter.
Subsequently, using established TAM trafficking strategies, we could
observe the inhibitory effect of DEX, a potent anti-inflammatory
drug, on TAM migration and its negative modulatory effects ontumor progression. Raw264.7 and CT26 cells were selected as
TAMs and a colon cancer model based on their use in previous
studies [19–21]. The introduction of reporter genes by retroviral or
lentiviral systems enables the long-term monitoring of infused
immune cells, stem cells, and cancer cells [22–24]. Thus, we
established reporter gene-expressing macrophage and colon cancer
cells using a retroviral or lentiviral system. Because the population
levels of migrated TAMs to tumor lesion are quite less, we selected the
highly sensitive reporter gene enhanced firefly luciferase, which has
10-fold to 9400-fold higher luciferase activity than firefly luciferase
and can be used to visualize even just a few cells in vivo [25]. To
monitor tumor progression with respect to migrated TAMs in vivo,
CT26 cells were engineered to coexpress Rluc and mCherry using the
lentiviral system; accordingly, both cell proliferation and tumor
growth could be examined by a combination of BLI and FLI in vitro
and in vivo.
TAMs promote the proliferation of cancer cells by upregulating
angiogenic factors [7,8]. Consistent with these findings, both in vitro
BLI and FLI revealed that Raw/effluc cells promoted the proliferation
of CT26/RM cells. Consistent with the in vitro findings, in vivo BLI
using Rluc showed the enhanced proliferation of CT26/RM cells
when Raw/effluc cells are coinjected with CT26/RM cells. Cancer
cells secrete several chemokine attractants, such as CCL2, CCL5,
CCL7, CCL8, CXCL12, VEGF, and CSF-1. These promote TAM
migration to tumor lesions [26]. Using a Transwell migration assay,
we also found that CM as a chemoattractant from CT26/RM cells
promotes the migration of Raw/effluc cells in a dose-dependent
manner. These finding suggest that Raw/effluc cells have TAM
characteristics and that both Raw/effluc and CT26/RM cells
are suitable for in vivo visualization of biological behavior in
tumor-bearing mice.
It has been proposed that TAMs are an important component in
the tumor microenvironment and are continuously recruited to
tumors via several chemoattractants, leading to a poor prognosis for
several types of cancers [7]. Serial monitoring of the dynamic
recruitment of TAMs is important to understand their biological role
in tumor microenvironments; accordingly, we tracked TAM
migration to CT26/RM tumor lesions using the effluc gene. Upon
transfer of Raw/effluc cells to tumor-bearing mice, they were observed
in the lung and rapidly moved to the spleen. Interestingly, on day 1
posttransfer, we detected migrated Raw/effluc cells in tumor lesions,
and BLI signals were still evident at day 4. Using multimodal reporter
gene-based imaging, we can find that the BLI signals of Raw/effluc
cells were consistent with the FLI signals from CT26/RM. Similar
with our finding, other groups have found the upregulation of
numerous chemotactic cytokines and angiogenic factors including
CCL2, CSF-1, VEGF, and TGF-β in CT26/DsRed cells cocultured
with Raw264.7/GFP CM by the use of microarray analysis, which
finally leads to the enhanced migration of Raw/GFP to CT26/DsRed
in vitro [20]. From findings of our and other group, we may postulate
that Raw/effluc is recruited to tumor lesions via chemokine attractants
secreted from CT26/RM tumors following the distribution of
infused Raw/effluc cells to several organs, even though the
mechanism for increased migration of macrophage to tumor lesion
is not completely addressed.
Several studies have shown that TAMs attracted by cancer cells
respond to tumor-derived molecules, leading to the production of
important growth factors and extracellular matrix enzymes and
eventually stimulating tumor proliferation, angiogenesis, and the
Figure 5. Evaluation of the effects of DEX on both TAM migration to tumor lesions and modulated tumor growth with BLI and FLI.
(A) Inhibition of TAMmigration to tumor lesions by DEX treatment. (B) Representative FLI imaging of tumor progression. (C) Quantification
ofmCherry signals and (D) relative increase of FLI signal in tumors. Tumor-bearingmicewere divided into three groups as follows: CT26/RM
alone, CT26/RM+Raw/effluc, and CT26/RM+Raw/effluc+DEX groups. Either vehicle or DEX was intraperitoneally injected to tumor-bearing
mice that received Raw/effluc. BLI for TAM imaging and FLI to assess tumor growth were performed. The relative increase (%) in
the signal was expressed based on a comparison between the FLI signal at day 0 and day 11. *CT26/RM versus CT26/RM+Raw/effluc,
**CT26/RM+Raw/effluc versus CT26/RM+Raw/effluc+DEX.
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have proven the increased expression levels of several chemotactic
cytokines and angiogenic growth factors such as TGFβ, VEGF,
CXCL2, and SDF-1α in Raw264.7 in response to CT26 CM by
microarray analysis, which result in the enhanced proliferation and
metastasis of CT26 cancer cells in in vitro and in vivo chicken egg
chorioallantoic membrane assay and may induce the hindrance of
killing of immune effectors like cytotoxic T lymphocyte, suggestingthe positive feedback mechanism in tumor microenvironments
between Raw264.7 macrophage and CT26 cancer cell. Consistent
with the findings of other groups, we can successfully find that the
migrated Raw/effluc cells promote tumor growth, which can be
observed from day 7 posttransfer of Raw/effluc cells using multimodal
reporter gene imaging.
Substantial numbers of new therapeutic reagents against TAMs
that allow for their attenuation or depletion as well as the inhibition of
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reliable and quantitative tools that are capable of monitoring TAM
migration and evaluating the effects of TAM on tumor progression
are required to investigate the therapeutic efficacy of anti-TAM
candidate drugs. We evaluated the effects of DEX, which is also
known as a proinflammatory cytokine inhibitor, on both TAM
migration into tumor lesions and tumor growth using our established
TAM imaging technique. DEX effectively regulates the expression of
inflammatory cytokines [30,31] and is widely used in cancer therapy
strategies [32–35]. We found that DEX effectively blocks the
recruitment of TAMs to tumors and subsequently inhibits enhanced
tumor growth by migrated TAMs. Although the mechanism
underlying the effects of DEX on the migration of macrophage as
well as the suppression of tumor growth was not fully elucidated in
this study, we may postulate this phenomenon as follows: Because
DEX treatment may result in the decrease of the proinflammatory
cytokines at the site of tumor and in serums, the number of
macrophages migrated to tumor lesion may be reduced. Subsequent-
ly, owing to DEX-induced reduction of number of macrophage
migrated to tumor lesion, the level of proinflammatory cytokines in
tumor microenvironment that enhance the tumor proliferation and
migration will be decreased, finally leading to the suppression of
promoted tumor progression. These results indicate that our TAM
imaging strategy can be used to validate the efficacy of candidate drugs
that modulate TAM effects in tumor microenvironments. Additionally,
our results indicate that DEX has great potential for applications with
conventional cancer therapies, such as chemotherapy and radiation
therapy, when therapeutic efficacy is hindered by TAMs.
We should address some limitations of our current study. First,
because in vivo tracking of TAMs migration to tumor lesion was
achieved by the use of macrophage cell line, it is difficult to
understand the accurate mechanism associated with TAMs migration
to tumor lesion as well as their involvements in promoted tumor
growth. In the future, we should focus on tracking the migration of
primary TAMs in living mice. Second, we focused on only one model
of tumor such as colon cancer. Next study might be conducted in
other types of tumor such as breast cancer, lung cancer, etc.
Conclusion
To our knowledge, this is the first study to simultaneously evaluate
the migration of TAMs to tumor lesions and the modulation of
tumor progression by migrated TAMs, as well as the efficacy of an
anti-TAM drug with multimodal reporter gene-based imaging in
immunocompetent mice with a colon cancer model. We expect that
our results will facilitate the development of new candidate drugs that
attenuate TAM functions or abolish its migration into tumor lesions.
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